Daniela Bota, MD of UC Irvine Health gives an overview of the AURA3 trial and the use of osimertinib in patients with advanced non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract 9005: CNS Response to Osimertinib in Patients (pts) with T790M-Positive Advanced NSCLC: Data from a Randomized Phase III Trial (AURA3)
Advertisement